股票代码：300363 股票简称：博腾股份 公告编号：2025-050 号 重庆博腾制药科技股份有限公司 关于实际控制人部分股份质押及解除质押的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）于近日接到公司控股 股东、实际控制人之居年丰先生函告，居年丰先生将其持有的公司部分股份分别 办理质押及解除质押等业务。具体情况如下： 一、股东股份质押及解除质押基本情况 注：上表中若出现总数与分项数值之和不符的情况，均为四舍五入原因造成。 3、股东股份累计质押情况 截至本公告披露日，公司控股股东、实际控制人居年丰先生、陶荣先生、张 和兵先生（居年丰、陶荣、张和兵三人为一致行动人）所持质押股份情况如下： | | | | 累计质押 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 持股数量 | 持股比 | 股份数量 | 持股份 | 总股本 | 已质押股份 | 占 ...

Group 1 - The A-share market experienced fluctuations on September 12, with a rebound in the innovative drug concept in the afternoon [1] - The Tianhong Innovative Drug ETF (517380) showed a "W" shaped reversal in the morning and continued to strengthen in the afternoon, rising by 1.50% with a trading volume exceeding 58 million yuan [1] - Notable stocks within the Tianhong Innovative Drug ETF included Nocare Pharma-U, which rose over 14%, and Zhaoyan New Drug, which hit the daily limit [1] Group 2 - The Biopharmaceutical ETF (159859) increased by 0.88%, with a trading volume exceeding 90 million yuan, featuring stocks like Junshi Biosciences-U and WuXi AppTec among the top gainers [1] - As of September 11, the Tianhong Innovative Drug ETF had seen a net inflow of over 79 million yuan over four consecutive days, while the Biopharmaceutical ETF had a net inflow of over 220 million yuan over three days [1] Group 3 - The Tianhong Innovative Drug ETF is the largest in the market, covering both A-shares and Hong Kong stocks, and is the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Select 50 Index [1] - The Biopharmaceutical ETF closely tracks the Guozheng Biopharmaceutical Index, which covers various sectors including innovative drugs, CXO, vaccines, and blood products [1] Group 4 - The National Medical Products Administration announced measures to optimize the review and approval of clinical trials for innovative drugs, aiming to complete reviews within 30 working days for eligible applications [1] - This initiative supports key national research and encourages global early-stage synchronized research and international multi-center clinical trials [1] Group 5 - Short-term outlook suggests that many innovative drug stocks have seen significant gains since the beginning of the year, which may lead to profit-taking in response to negative news [2] - The biotech sector in China is expected to maintain high investment value due to continuous innovation breakthroughs and improved profitability [2] Group 6 - The Hong Kong innovative drug sector reported a net profit of 1.8 billion yuan in the first half of the year, marking its first profit since turning around [2] - The industry is entering a new cycle driven by profitability, with leading companies achieving profits through the commercialization of products and accelerating the conversion of research value [2]

Core Insights - The stock price of Boteng Co., Ltd. decreased by 2.03% on September 12, trading at 25.06 CNY per share with a market capitalization of 13.669 billion CNY [1] - The company has seen a year-to-date stock price increase of 58.91%, but a recent decline of 3.24% over the last five trading days [1] Financial Performance - For the first half of 2025, Boteng Co., Ltd. reported a revenue of 1.621 billion CNY, representing a year-on-year growth of 19.88%, and a net profit attributable to shareholders of 27.0595 million CNY, which is a significant increase of 115.91% year-on-year [2] - Cumulatively, the company has distributed 1.193 billion CNY in dividends since its A-share listing, with 866 million CNY distributed over the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Boteng Co., Ltd. was 52,700, a decrease of 0.75% from the previous period, with an average of 9,502 circulating shares per shareholder, an increase of 0.75% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Tianhong Medical Innovation A, with notable changes in their holdings [3] Business Overview - Boteng Co., Ltd. specializes in CDMO services for chemical raw materials, chemical formulations, and biological CDMO services, including gene and cell therapies [1] - The company's revenue composition includes 66.81% from late-stage clinical and commercialization, 25.76% from early-stage clinical, and 7.11% from emerging businesses [1] Market Position - The company is classified under the pharmaceutical and biological industry, specifically in medical service and medical research outsourcing [1] - Boteng Co., Ltd. is associated with several concepts including CRO, cancer treatment, innovative drugs, and biomedicine [1]

截至8月29日，博腾股份股东户数5.27万，较上期减少0.75%；人均流通股9502股，较上期增加0.75%。 2025年1月-6月，博腾股份实现营业收入16.21亿元，同比增长19.88%；归母净利润2705.95万元，同比增 长115.91%。 分红方面，博腾股份A股上市后累计派现11.93亿元。近三年，累计派现8.66亿元。 机构持仓方面，截止2025年6月30日，博腾股份十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1075.89万股，相比上期增加238.86万股。天弘医药创新A（010654）位居第六大流通股 东，持股639.80万股，相比上期减少51.39万股。南方中证1000ETF（512100）位居第九大流通股东，持 股302.18万股，为新进股东。华宝中证医疗ETF（512170）、中欧医疗健康混合A（003095）、中信建 投医改A（002408）退出十大流通股东之列。 9月9日，博腾股份盘中上涨2.02%，截至09:58，报26.22元/股，成交2.03亿元，换手率1.58%，总市值 143.02亿元。 资金流向方面，主力资金净流出52.23万元，特大单买入975.58万 ...

Core Points - The company announced a change in the purpose of its share repurchase program, shifting from "for implementing equity incentives or employee stock ownership plans" to "for cancellation and reduction of registered capital" [2] - A total of 2,022,344 shares from the 2022 repurchase will be canceled, reducing the total share capital from 545,464,520 shares to 543,442,176 shares [2] - The registered capital will decrease from RMB 545,464,520 to RMB 543,442,176 following the cancellation of shares [2] - The company has notified creditors of their rights to request debt repayment or guarantees within 45 days from the announcement date [2] - If creditors do not exercise their rights within the specified period, the share cancellation will proceed according to legal procedures [2]

Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 will be held on September 8, 2025 [2] - The meeting will review and approve several proposals, including the proposal to change the purpose of part of the repurchased shares and to cancel them [2]

Group 1 - The company announced the cancellation of part of the repurchased shares and a capital reduction on September 8, 2025 [1] - The board meetings held on August 21, 2025, and the extraordinary shareholders' meeting on September 8, 2025, approved the change in the purpose of the repurchased shares [1] - The repurchased shares, originally intended for employee stock incentive plans, will now be used for cancellation and reduction of registered capital [1] Group 2 - A total of 2,022,344 shares will be canceled, reducing the total share capital from 545,464,520 shares to 543,442,176 shares [1] - The registered capital will decrease from RMB 545,464,520 to RMB 543,442,176 following the cancellation [1] - Creditors have 45 days from the announcement date to claim debts or request guarantees due to the capital reduction [1]

1、本次股东会召开期间没有增加、否决或变更议案情况发生； 2、本次股东会不涉及变更前次股东会决议； 股票代码：300363 股票简称：博腾股份 公告编号：2025-048 号 重庆博腾制药科技股份有限公司 2025 年第一次临时股东会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 同意 240,358,789 股，占参加本次股东会的股东所持有表决权股份总数 99.9297%；反对 127,300 股，占参加本次股东会的股东所持有表决权股份总数 0.0529%；弃权 41,910 股，占参加本次股东会的股东所持有表决权股份总数 0.0174%。 3、本次股东会采取现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 重庆博腾制药科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东会于 2025 年 9 月 8 日（星期一）14:30 在重庆市北碚区云图路 7 号公司研发 大楼 2-2 会议室以现场投票与网络投票相结合的方式召开。本次股东会由公司董 事会召集，董事长居年丰因其他公务安排无法履行本次股东会主持人职务，经公 司半 ...

北京市万商天勤律师事务所 关于重庆博腾制药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 1 北京市万商天勤律师事务所关于 重庆博腾制药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 致：重庆博腾制药科技股份有限公司 北京市万商天勤律师事务所（以下简称"本所"）接受重庆博腾制药科技股 份有限公司（以下简称"公司"）的委托，指派律师出席了公司召开的 2025 年 第一次临时股东会。根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性 文件以及《重庆博腾制药科技股份有限公司章程》（以下简称"《公司章程》"） 的要求，就公司 2025 年第一次临时股东会（以下简称"本次临时股东会"）的 相关事宜出具本法律意见书。 公司已向本所律师提供了本所律师认为出具本法律意见书必要的文件资料， 本所律师对该等文件和资料进行了核查、验证，并据此出具法律意见。 本所律师仅就本次临时股东会的召集、召开程序、出席会议人员资格、召 集人资格及会议表决程序、表决结果是否符合《公司法》、《股东会规则》以及 《公司章程》发表意见。 本所律师同意 ...

重庆博腾制药科技股份有限公司（以下简称"公司"）分别于 2025 年 8 月 21 日召开第六届董事会第三次会议和第六届监事会第二次会议、于 2025 年 9 月 8 日召开 2025 年第一次临时股东会，审议通过《关于变更部分回购股份用途并 注销的议案》，同意对公司于 2022 年 8 月 4 日召开的第五届董事会第六次临时 会议审议通过的《关于以集中竞价交易方式回购股份的议案》的回购股份（以下 简称"2022 年回购"）用途进行变更，由"用于实施股权激励或员工持股计划" 变更为"用于注销并减少公司注册资本"，并对 2022 年回购的全部股份，共计 2,022,344 股，予以注销。具体情况详见公司分别于 2025 年 8 月 23 日在巨潮资 讯网（www.cninfo.com.cn）披露的《关于变更部分回购股份用途并注销的公告》 （公告编号：2025-045号）、于2025 年9 月8日在巨潮资讯网（www.cninfo.com.cn） 披露的《2025 年第一次临时股东会决议公告》（公告编号：2025-048 号）。 上述注销实施完毕后，公司总股本将由 545,464,520 股变更为 543,442 ...